SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-002752
Filing Date
2022-01-05
Accepted
2022-01-05 17:06:01
Documents
18
Period of Report
2022-01-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d283429d8k.htm   iXBRL 8-K 30170
2 EX-1.1 d283429dex11.htm EX-1.1 204692
3 EX-5.1 d283429dex51.htm EX-5.1 10425
4 EX-99.1 d283429dex991.htm EX-99.1 5073
5 EX-99.2 d283429dex992.htm EX-99.2 9849
9 GRAPHIC g283429g0105095623983.jpg GRAPHIC 2771
10 GRAPHIC g283429g0105095624155.jpg GRAPHIC 1546
  Complete submission text file 0001193125-22-002752.txt   450075

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA itci-20220104.xsd EX-101.SCH 2933
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20220104_lab.xml EX-101.LAB 17373
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20220104_pre.xml EX-101.PRE 10980
12 EXTRACTED XBRL INSTANCE DOCUMENT d283429d8k_htm.xml XML 3214
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 22512167
SIC: 2834 Pharmaceutical Preparations